In the first clinical study concerning the effect of Bortezomib administration on bone remodeling markers, Terpos et al. have shown significantly reduced serum levels of sRANKL, DKK-1, CTX, and TRACP-5b after four cycles of therapy, irrespective of treatment response, thus leading to the normalization of bone remodeling in relapsed myeloma patients [71]. The gene discussed is DKK1; the disease is plasma cell myeloma.